215 Users Online
Clinical Trial Kits Market by Service Type - Kitting Solutions (Drugs Kits | Sample Collection Kits)
The global clinical trial kits market was valued at around US$ 1.3 Bn in 2021. With a projected CAGR of 12.3% for the next ten years; the market is likely to reach a valuation of US$ 4.6 Bn by the end of 2032. The increasing number of clinical trials performed globally is driving the clinical trial kits market.
|
Report Attributes |
Details |
|
Estimated Market Value (2022E) |
US$ 1.5 Bn |
|
Forecasted Market Value (2032F) |
US$ 4.6 Bn |
|
Global Market Growth Rate (2022-2032) |
12.3% CAGR |
|
United States Growth Rate (2022-2032) |
13.1% CAGR |
|
Key Companies Covered |
|
Persistence Market Research’s analysis reveals that most of the market revenue is grossed from logistics service-type clinical trial kits. On the other hand, clinical trial kits for phase III will be the most lucrative with an 11.4% of CAGR during 2022 – 2032.
FREE Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
The global market for clinical trial kits expanded with a CAGR of 9.9% during 2015-2021. The global clinical trial kits market is expected to create an absolute dollar opportunity of more than US$ 3.2 Bn during 2022-2032.
In 2021, the global market size of clinical trial kits was valued at US$ 1.3 Bn and is estimated to increase to a valuation of US$ 1.5 Bn in 2022. The increasing technological advancement in clinical trials has increased the use of clinical trial kits. Furthermore, the rise in the use of home-based testing has led to further medical research being pursued remotely. As testing is made possible through remote technology and increased adoption, it will help to alleviate doctors' workloads, as is made clear during frequent testing and patient monitoring. Increasing the use of remote testing and considering virtual technologies by professionals is expected to drive the market for medical research.
The global clinical trial kits market is predicted to grow ahead at a CAGR of 12.3% and sales worth US$ 4.6 Bn during 2022 - 2032. The US will continue to be the largest user of clinical trial kits throughout the analysis period accounting for over US$ 1.2 Bn absolute dollar opportunity in the coming 10-year epoch.
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized VersionThe advantage of DtP clinical trials as they are cost-effective and easy to conduct comparing traditional clinical trials has been motivating the pharmaceuticals and drug manufacturing companies to choose DtP clinical trials. In DtP clinical trials samples are collected from the patient’s home and then transferred to the testing facilities and the drugs are directly delivered to the patient’s home. Quality trial kits are to be used because the damaged trial drugs can have big consequences. The demand for DtP clinical trials is increasing which is propelling the growth of the clinical trial kits market.
The transportation of the samples and medicines with optimum temperature conditions is a key factor in the clinical trials. The proper delivery of the samples to the testing setup and the delivery of the drugs to the right patient at right time is important.
Certain samples and medicines should be needed to preserve at a certain temperature and temperature-controlled shipping containers are more expensive to use than standard shippers are. Another challenge is that the chances of error are high when the individuals do the sample collection. These factors are expected to restrain the growth of the clinical trial kits market.
Sales Team
Client Partner
How is the demand for Clinical Trial Kits shaping up in North America?
The increasing incidences of cancer have increased the demand for phase III clinical studies in North America. Furthermore, the region's pharmaceutical and drug development companies are shifting to virtual and decentralized clinical trials, which will drive the demand for clinical trial kits in North America over the forecasted years.
US Clinical Trial Kits Market Analysis
According to Clinical Trials.gov, about 32% of the total registered clinical studies are performed in the US. The rapid adoption of decentralized clinical trials is driving the clinical trial kits market in the US. The clinical trial kits market in the US is expected to reach a valuation of US$ 1.2 Bn by 2032.
China Clinical Trial Kits Market Analysis
The Clinical Trial kits market in China is forecasted to reach a valuation of US$ 381.3 Mn by the end of 2032. China has developed a clinical trial infrastructure with skilled experts and a well-developed network of experienced therapeutic experts. In addition, the large number of the patient pool who are eligible for the clinical trial is also driving the market in China. The clinical trial kits market in China is expected to create an absolute dollar opportunity of US$ 74.8 Mn over the 2022-2032 period.
U.K. Clinical Trial Kits Market Analysis
The market in the U.K. is projected to reach US$ 221 Mn by 2032, growing at a CAGR of 12.8% during the forecast period. The market is expected to gross an absolute dollar opportunity of US$ 56 Mn during 2022 – 2032.
Japan Clinical Trial Kits Market Analysis
In Japan, the market is expected to reach US$ 239 Mn by 2032. Growing at a CAGR of 14% during the forecast period, the market is projected to garner an absolute dollar opportunity of US$ 174 Mn.
Why Logistics service type is driving the demand for clinical trial kits?
The increasing number of clinical trials performed and the need to transport the samples and medicines without any damage are boosting the growth of this segment. The main function of the logistics in the clinical trial process is to transfer the samples to labs very quickly as possible. The logistics segment accounted for a CAGR of 11.3% during 2015-2021.
How Phase III of clinical trials is driving the clinical trial kits market?
Phase III study of clinical trials includes a large patient population and is conducted in many places at the same time is the key factor driving the market. Phase III studies generally take longer times compared to Phase I and Phase II studies. Phase III studies can detect the side effects of the specific drugs, which passed the phase II, study of the clinical trial. The market through Phase III clinical trials accounted a CAGR of 9.1% during 2015-2021.
At present, clinical trial kit manufacturers are largely actively expanding their manufacturing facilities to boost production. The key companies operating in the clinical trial kits market include Azenta Life Sciences, Q2 Solutions, Patheon (Thermo fisher scientific), LabCorp drug development, Charles River Laboratories, LabConnect, Almac group, Precision medicine group, Cerba research, Alpha Laboratories Ltd, Marken SAS, and Clinigen.
Some of the recent developments by key providers of clinical trial kits are as follows:
Similarly, the team at Persistence Market Research has tracked recent developments related to companies manufacturing clinical trial kits, which is available in the full report.
By Service Type:
By Phase:
By Region:
The global clinical trial kits market was valued at US$ 1.3 Bn in 2021.
The global clinical trial kits market is set to witness a high growth rate of 12.3% over the forecasted period and be valued at US$ 4.6 Bn by 2032.
The Clinical Trial Kits Market expanded at a CAGR of 9.9% from 2015 through 2021.
Azenta Life Sciences, Q2 Solutions, Patheon, LabCorp Drug Development, and Charles River Laboratories are the key suppliers of Clinical Trial Kits that are shaping the market.
The US, UK, China, Japan, and South Korea are expected to drive the most sales growth of clinical trial kits.
The market in the US has forecasted to account for over 35% of the global market share in 2032.
